Drug Trial Radar · NCT02673931
GLP-1 and Hyperoxia for Organ Protection in Heart Surgery
Last checked: Nov 20, 2026Latest source record: Aug 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,400
Actual
Start
Feb 2016
Primary completion
Sep 2024
Study completion Sep 2024
Sponsor
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 4, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients undergoing open heart surgery are at risk of suffering damage to the heart, brain and kidneys. This study is designed as a 2-by-2 randomized clinical trial with the purpose of investigating the organ protective effects of the glucagon-like-peptide-1 (GLP-1) agonist Exenatide versus placebo and restrictive versus liberal oxygenation during weaning from cardio-pulmonary bypass.
Conditions
- Coronary Disease
- Shock, Cardiogenic
- Renal Failure
- Stroke
- Brain Injury
- Aortic Valve Disease
Interventions
Byetta (Lilly, Exenatide)Drug
See description of arms
Conoxia (AGA, oxygen)Drug
See description arms
20% Human AlbuminDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time in days to the first occurring of the following co-primary end-points throughout the follow-up periodTime frame: Minimum 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rigshospitalet - Copenhagen University Hospital
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.